1. Pink Sheet
  2. >>Agency Leadership
  3. >>US FDA

FDA Sidelines Chief Spokesperson As It Grapples With Fallout From COVID-19 Plasma Authorization

 
• By Brenda Sandburg

Emily Miller, who joined FDA a few days before its controversial roll out of emergency use authorization for convalescent plasma, remains at the agency. Situation shows importance of sticking to science-based decisions, former FDA officials say.

Clouds-Lightning-Storm_1200x675
FDA dealing with political firestorm after COVID-19 convalescent plasma authorization • Source: Shutterstock

The political firestorm engulfing the US Food and Drug Administration continues, with its chief spokesperson, Emily Miller, being sidelined following fierce criticism of the way the agency handled an emergency use authorization for COVID-19 convalescent plasma. The situation shows the consequences of FDA straying from its strictly science-based approach and the turmoil going on within the agency as it deals with pressures inside and outside the Trump Administration.

The sidelining of Miller, first reported by the New York Times, suggests she was being held accountable, at least in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA

AI Will Bolster, Not Squelch, Patient Voice In Clinical Research, US FDA Says

 
• By Sue Sutter

Artificial intelligence tools used for clinical research should be developed with input from patients and focus on their needs and abilities, FDA experts said.

US FDA’s Top Cell and Gene Therapy Regulators Forced Out

 
• By Sarah Karlin-Smith

Office of Therapeutic Products Director Nicole Verdun and her deputy Rachael Anatol were escorted out of FDA headquarters on June 18. Disagreements over CAR-T regulation and Capricor’s DMD treatment may be to blame.

First Among Equals: US FDA CBER Director Prasad Gains Agency-Wide Authority

 
• By Bridget Silverman

As Chief Medical and Scientific Officer, Vinay Prasad will advise the FDA Commissioner on cross-cutting issues, provide strategic leadership and be a public face of the agency.

BIO Notebook: Policy Problems, ACIP’s Future, BI Is Popular, Makary On FDA-Industry Ties

 
• By Sarah Karlin-Smith and Mandy Jackson

Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.

More from Agency Leadership